Harvard Bioscience Inc (HBIO) — SEC Filings
Harvard Bioscience Inc (HBIO) — 35 SEC filings. Latest: 8-K (Dec 17, 2025). Includes 17 8-K, 6 10-Q, 6 SC 13G/A.
View Harvard Bioscience Inc on SEC EDGAR
Overview
Harvard Bioscience Inc (HBIO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 5, 2025: On December 5, 2025, Harvard Bioscience, Inc. filed an 8-K report. The filing indicates "Other Events" as the item information, with no specific details provided in the excerpt regarding the nature of these events, any associated financial figures, or other involved parties.
Sentiment Summary
Across 35 filings, the sentiment breakdown is: 5 bearish, 30 neutral. The dominant filing sentiment for Harvard Bioscience Inc is neutral.
Filing Type Overview
Harvard Bioscience Inc (HBIO) has filed 17 8-K, 6 10-Q, 1 8-K/A, 1 DEF 14A, 2 10-K, 6 SC 13G/A, 2 SC 13G with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (35)
Risk Profile
Risk Assessment: Of HBIO's 25 recent filings, 4 were flagged as high-risk, 13 as medium-risk, and 8 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $62.815M |
| Net Income | -$53.853M |
| EPS | -$1.22 |
| Debt-to-Equity | 4.54 |
| Cash Position | $6.817M |
| Operating Margin | -80.1% |
| Total Assets | $77.992M |
| Total Debt | $33.967M |
Key Executives
- Europe and North America
- Holliston, MA
- Jeffrey S. Glass
- James F. Lark, Jr.
- James Green
Industry Context
The life sciences tools and diagnostics industry is characterized by innovation and consolidation. Companies like Harvard Bioscience operate in a competitive landscape requiring significant R&D investment. Recent trends include increased demand for advanced research tools, but also pressure on pricing and profitability due to economic uncertainties and supply chain challenges.
Top Tags
corporate-governance (5) · delisting (4) · listing-standards (4) · 10-Q (4) · financials (4) · executive-compensation (3) · management-change (3) · 8-k (3) · disclosure (2) · Net Loss (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $53.853M | Increased significantly from $12.423M in prior year, primarily due to goodwill impairment. |
| Goodwill Impairment | $47.951M | Major non-cash charge impacting net loss for the nine months ended September 30, 2025. |
| Total Revenues | $62.815M | Decreased by 9.7% from $69.579M year-over-year for the nine-month period. |
| Outstanding Debt | $34.0M | Under the Credit Agreement, creating substantial doubt about going concern. |
| Debt Refinancing Deadline | Dec 5, 2025 | Critical date for the company to avoid an event of default. |
| Total Stockholders' Equity | $14.068M | Plummeted from $63.340M at December 31, 2024, reflecting the net loss and impairment. |
| Total Assets | $77.992M | Decreased significantly from $126.644M at December 31, 2024, largely due to goodwill impairment. |
| Cash and Cash Equivalents | $6.817M | Increased from $4.108M at December 31, 2024, despite overall financial distress. |
| Basic and Diluted Loss Per Share | -$1.22 | Significantly worse than -$0.29 in the prior year, reflecting the increased net loss. |
| Revenue Decrease | 9.7% | Percentage decline in total revenues for the nine months ended September 30, 2025, compared to 2024. |
| Revenue from continuing operations | $55.2M | Increased from $52.8 million in 2024, a 4.5% growth. |
| Net loss from continuing operations | -$2.5M | A significant decline from $1.2 million net income in 2024. |
| Research and Development Expense | $6.8M | Increased from $6.1 million in 2024. |
| General and Administrative Expense | $12.5M | Increased from $11.8 million in 2024. |
| Selling and Marketing Expense | $10.2M | Increased from $9.8 million in 2024. |
Frequently Asked Questions
What are the latest SEC filings for Harvard Bioscience Inc (HBIO)?
Harvard Bioscience Inc has 35 recent SEC filings from Jan 2024 to Dec 2025, including 17 8-K, 6 10-Q, 6 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of HBIO filings?
Across 35 filings, the sentiment breakdown is: 5 bearish, 30 neutral. The dominant sentiment is neutral.
Where can I find Harvard Bioscience Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Harvard Bioscience Inc (HBIO) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Harvard Bioscience Inc?
Key financial highlights from Harvard Bioscience Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for HBIO?
The investment thesis for HBIO includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Harvard Bioscience Inc?
Key executives identified across Harvard Bioscience Inc's filings include Europe and North America, Holliston, MA, Jeffrey S. Glass, James F. Lark, Jr., James Green.
What are the main risk factors for Harvard Bioscience Inc stock?
Of HBIO's 25 assessed filings, 4 were flagged high-risk, 13 medium-risk, and 8 low-risk.
What are recent predictions and forward guidance from Harvard Bioscience Inc?
Forward guidance and predictions for Harvard Bioscience Inc are extracted from SEC filings as they are enriched.